Business
SERA PROGNOSTICS ANNOUNCES PUBLICATION OF DATA DEMONSTRATING IMPROVED PERFORMANCE OF ITS PRETRM® TEST WITH MORE PRECISE GESTATIONAL AGE
Results show that the validated proteomics predictor has even greater predictive performance to determine risk of spontaneous preterm birth SALT LAKE CITY,
About this update from Sera Prognostics, Inc.
[{"type":"text","content":"Results show that the validated proteomics predictor has even greater predictive performance to determine risk of spontaneous preterm birth\nSALT LAKE CITY, May 19, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the publication of improved PreTRM® test performance using women from the Proteomic Assessment of Preterm Risk (PAPR) clinical study whose pregnancy outcomes are aligned with updated ACOG gestational age dating guidelines. The newly published article reports:\n\n \n \n \n \n \n \n\n \nA greater observed sensitivity of 88% at 75% specificity, which represent increases of 17% and 1%, respectively, relative to all subjectsAn improved performance was also demonstrated over an expanded 18-20 weeks' gestational age time interval for performing PreTRM testing, consistent with the timeframe of routine obstetric visits during pregnancyA negative predictive value of 99% for the test, at its validated threshold\"Beyond increased performance, these data show that the PreTRM® test can also be offered more conveniently to women over a broader time interval during pregnancy, typically months before preterm delivery occurs,\" said Michael Foley, MD, Sera's Chief Medical Officer. \"A PreTRM® test higher risk result reflects a similar risk as is revealed by traditional assessment techniques, but the PreTRM® test identifies far more patients who are at risk of premature delivery. Furthermore, the reported 99% negative predictive value of the PreTRM® test means that women not found to be at higher risk of preterm delivery can have very high confidence of not delivering a premature infant.\"\n\"These new data demonstrate substantially improved PreTRM® test predictive performance over an expanded blood draw window when gestational age is known with more accuracy, as the first and only broadly validated commercially available blood test for prematurity risk is made even more available to physicians and their patients,\" said Gregory C. Critchfield, MD, MS, Chairman and CEO of Sera Prognostics. \"Sera's pioneering work in the pregnancy space highlights the power of our proteomics and bioinformatics approach to provide valuable information to women and their physici...